- SEK11.25bn
- SEK11.07bn
- SEK2.06bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 35.56 | ||
| PEG Ratio (f) | 2.57 | ||
| EPS Growth (f) | 16.03% | ||
| Dividend Yield (f) | 1.61% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.93 | ||
| Price to Tang. Book | 15.48 | ||
| Price to Free Cashflow | 59.87 | ||
| Price to Sales | 5.74 | ||
| EV to EBITDA | 22.83 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.19% | ||
| Return on Equity | 6.59% | ||
| Operating Margin | 15.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 1,092.28 | 1,232 | 1,566 | 1,872 | 2,056 | 2,067.5 | 2,279 | 13.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -7.28 | +18.2 | +40.6 | -1.28 | -24.76 | +8.48 | +30.97 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biotage AB is a Sweden-based company that develops and sells systems, consumables and services in the field of life sciences. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The Company offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotage’s offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Company’s offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.
Directors
- Torben Joergensen CHM (68)
- Tomas Blomquist PRE (50)
- Maja Nilsson CFO
- Scott Carr CEX (54)
- Andreas Juhlin CEX (47)
- Petra Duprez CHO (56)
- Rikke Rytter EVP (53)
- Lisa Egelrud EVP (46)
- Olof Nord EVP (46)
- Magnus Nordstedt EVP (51)
- Anders Wikstrom EVP (47)
- Jon-Sverre Schanche CSO (64)
- Lars Backman OTH (59)
- Love Amcoff DRC (46)
- Mark Bradley DRC (58)
- Annika Gardlund DRC (54)
- Asa Hedin DRC (58)
- Thomas Eklund IND (54)
- Karolina Lawitz IND (64)
- Peter Von Ehrenheim IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 7th, 1997
- Public Since
- June 30th, 2000
- No. of Shareholders
- 7,313
- No. of Employees
- 622
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm- Shares in Issue
- 80,049,272
- Address
- Vimpelgatan 5, UPPSALA, 753 18
- Web
- https://www.biotage.com/
- Phone
- +46 18565900
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for BIOT
Q3 2025 Biotage AB Earnings Call
Q3 2025 Biotage AB Earnings Release
Similar to BIOT
Acarix AB
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Biotage AB share price?
As of Today at 19:36 UTC, shares in Biotage AB are trading at SEK140.60. This share price information is delayed by 15 minutes.
How has the Biotage AB share price performed this year?
Shares in Biotage AB last closed at SEK140.60 and the price had moved by -14.63% over the past 365 days. In terms of relative price strength the Biotage AB share price has underperformed the FTSE Global All Cap Index by -16.77% over the past year.
What are the analyst and broker recommendations for Biotage AB?
The overall consensus recommendation for Biotage AB is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Biotage AB dividend yield?
The Biotage AB dividend yield is 1.17% based on the trailing twelve month period.
Does Biotage AB pay a dividend?
Last year, Biotage AB paid a total dividend of SEK1.65, and it currently has a trailing dividend yield of 1.17%.Looking ahead, the next dividend pay date is 2025-05-02.
When does Biotage AB next pay dividends?
We do not have data on when Biotage AB is to next pay dividends. The historic dividend yield on Biotage AB shares is currently 1.17%.
How do I buy Biotage AB shares?
To buy shares in Biotage AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biotage AB?
As of the previous close price of SEK140.60, shares in Biotage AB had a market capitalisation of SEK11.25bn.
Where are Biotage AB shares listed?
Here are the trading details for Biotage AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: BIOT
What kind of share is Biotage AB?
Based on an overall assessment of its quality, value and momentum Biotage AB is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biotage AB share price forecast for 2025?
The analyst consensus target price for shares in Biotage AB is SEK141.00. That is 0.28% above the last closing price of SEK140.60.
Analysts covering Biotage AB currently have a consensus Earnings Per Share (EPS) forecast of SEK3.60 for the next financial year.
Find out moreWhat is the trend in the Biotage AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotage AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -12.68%.
As of the last closing price of SEK140.60, shares in Biotage AB were trading -8.79% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biotage AB PE Ratio?
The Biotage AB PE ratio based on its reported earnings over the past 12 months is 35.56. The shares last closed at SEK140.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biotage AB?
Biotage AB's management team is headed by:
- Torben Joergensen - CHM
- Tomas Blomquist - PRE
- Maja Nilsson - CFO
- Scott Carr - CEX
- Andreas Juhlin - CEX
- Petra Duprez - CHO
- Rikke Rytter - EVP
- Lisa Egelrud - EVP
- Olof Nord - EVP
- Magnus Nordstedt - EVP
- Anders Wikstrom - EVP
- Jon-Sverre Schanche - CSO
- Lars Backman - OTH
- Love Amcoff - DRC
- Mark Bradley - DRC
- Annika Gardlund - DRC
- Asa Hedin - DRC
- Thomas Eklund - IND
- Karolina Lawitz - IND
- Peter Von Ehrenheim - IND